Quantitative immunohistochemistry of estrogen receptor in breast cancer "much ado about nothing!"

Applied Immunohistochemistry and Molecular Morphology

Volumn 16, Issue 2, 2008, Pages 105-107

  Nadji, Mehrdad ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b UM JMH   (United States)

Author keywords

Breast cancer; Estrogen receptor; Immunohistochemistry; Quantitative immunohistochemistry

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; TAMOXIFEN;

BREAST CANCER; HORMONE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL INFORMATION; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; BREAST TUMOR; CHEMISTRY; METHODOLOGY; REPRODUCIBILITY;

BREAST NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS;

EID: 46749124761     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3181607323     Document Type: Review

References (25)

1. Taylor CR. Paraffin section immunocytochemistry for estrogen receptor: the time has come. Cancer. 1996;77:2419-2422.
2. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
3. Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer. 1996;74:1445-1451.
4. Harvey JM, Clark GM, Osborne CK, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17:1474-1481.
5. Regan MM, Viale G, Mastropasqua MG, et al. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst. 2006;98:1571-1581.
6. Goulding H, Pinder S, Cannor P, et al. A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol. 1995;26:291-294.
7. Pertschuk LP, Feldman JG, Kim YD, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spg in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996;77:2514-2519.
8. Werner M, Chott A, Fabiano A, et al. Effect of formalin fixation and processing on immunohistochemistry. Am J Surg Pathol. 2000;24:1016-1019.
9. Goldstein NS, Ferkowicz M, Odish E, et al. Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma. Am J Clin Pathol. 2003; 120:86-92.
10. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancer. Am J Clin Pathol. 2005;123: 21-27.
11. Leong As-Y, Milios J. Comparison of antibodies to estrogen and progesterone receptors and the influence of microwave-antigen retrieval. Appl Immunohistochem. 1993;1:282-288.
12. Umemura S, Itoh J, Itoh H, et al. Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? Appl Immunohistochem Mol Morphol. 2004;12:8-13.
13. von Wasielewski R, Mengel M, Nolte M, et al. Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J. 1998;4:33-40.
14. Santeusanio G, Mauriello A, Ventura L, et al. Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule. Appl Immunohistochem Mol Morphol. 2000;8: 275-284.
15. Collin LC, Botero ML, Schnitt SJ. Bimodal frequency distribution of estrogen receptor immunohistochemistry staining results in breast cancer. Am J Clin Pathol. 2005;123:16-20.
16. Hodi Z, Chakrabarti J, Lee AHS, et al. The reliability of assessment of estrogen receptor expression on needle core biopsy specimens of invasive carcinomas of breast. J Clin Pathol. 2007;60:299-302.
17. Schmitt FC, Bento MJ, Amendoeira I. Estimation of estrogen receptor content in fine-needle aspirates from breast cancer using the monoclonal antibody 1D5 and microwave oven processing: correlation with paraffin embedded and frozen sections determinations. Diagn Cytopathol. 1995;13:347-351.
18. Zidan A, Christie Brown JS, Peston D, et al. Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma. J Clin Pathol. 1997;50:27-29.
19. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer. J Natl Cancer Inst. 2001;93:979-989.
20. Fisher ER, Anderson S, Dean S, et al. Solving the dilemma of the immunohistochemical and other methods used for scoring estrogen receptor and progesterone receptor in patients with invasive breast carcinoma. Cancer. 2004;103:164-173.
21. Ali S, Coombs RC. Endocrine-responsive breast cancer and strategies for combating resistance. Nat Rev Ca. 2002;2:101-112.
22. Johnson MD, Zou H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85:151-159.
23. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenomic determinants of outcome with tamoxifen therapy: findings from the randomized North Central Cancer Treatment Group adjuvant breast cancer trial 89-30-52. Breast Cancer Res Treat. 2004;88:S35.
24. Lloveras B, Monzo M, Colomer R, et al. Letrozole efficacy is related to human aromatase CYP19 single nucleotide polymorphisms (SNP's) in metastatic breast cancer patients. J Clin Oncol. 2004;22: 507-511.
25. Fabrice A, Lajos P. Molecular classification of breast cancer: implication for selection of adjuvant chemotherapy. Nat Clin Pract Oncol. 2006;3:621-632.